Special Offer: Get 50% off your first 2 months when you do one of the following
Personalized offer codes will be given in each session

A State-of-the-Art Expression Platform for Expanding the Boundaries of Standard and Complex Therapeutic Protein Manufacturing

About This Webinar

Sponsored by: ATUM-Rentschler

Over the last decades, the Pharmaceutical industry has pivoted from a chemistry-driven one to one focused on biologics. ATUM has developed Leap-In, a transposon-based platform that enables the rapid generation of exceptionally stable, high producing cell lines for biological therapeutics with excellent precision. Rentschler Biopharma has established the high performing Rentschler Expression Platform, by combining transposase mediated gene transfer with a well-proven host cell line. Based on case studies, we will demonstrate how to leverage this promising technology for a fast and efficient screening platform. The enhanced gene expression due to customized vector design, inherent stability, and optimal project timelines, through seamless integration into a well-characterized USP platform process, translates to optimal therapeutic protein production.

Privacy Policy

Who can view: Everyone
Webinar Price: Free
Webinar ID: 5459105c9b4d
Featured Presenters
Webinar hosting presenter
Director Process Science for Cell Line Development and Genotypic Characterization, Rentschler Biopharma
Sebastian Schwamb is Director Process Science for Cell Line Development and Genotypic Characterization with Rentschler Biopharma, with headquarters in Laupheim Germany and a site in Milford, MA, USA. In his role, Sebastian is leading the development of the new Rentschler Expression Platform as well as driving the implementation of all requirements to execute genotypic characterization analysis under cGMP-compliant conditions.

Sebastian has almost 10 years’ experience in the biopharmaceutical industry. This includes working as a provisional section head and permanent lab head for upstream process development, as well as process engineer for cell line development in big pharma (Sanofi) and Biotech (Ganymed Pharmaceuticals). Sebastian joined Rentschler Biopharma in 2020.
Webinar hosting presenter
Amalgamator of Business and Biology, ATUM
Dr. Oren Beske joined ATUM in 2019 and brings nearly 20 years of industry experience to the team. Notably, Dr. Beske was President of Aragen Biosciences, Inc. where he led a multidisciplinary team to bring value added services to the biologics industry. Most recently, he served as the CEO of Alloy Therapeutics, Inc. a start-up antibody discovery platform company. Dr. Beske received a BS in Physiology and Biochemistry from CSULB and his Ph.D. in Cell Biology from UC San Francisco.